Skip to content

Comparison of Cardiac Resynchronisation Therapy (CRT) Response Using High Frequency (HF) - ECG or Q-LV Guided Optimisation for Left Ventricular, Pacing Site.

Comparison of Cardiac Resynchronisation Therapy (CRT) Response Using High Frequency (HF) - ECG or Q-LV Guided Optimisation for Left Ventricular, Pacing Site

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05829876
Enrollment
180
Registered
2023-04-26
Start date
2023-10-31
Completion date
2025-07-31
Last updated
2024-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

The research aims to compare the response of Cardiac Resynchronisation Therapy (CRT) using HF ECG guided or the conventional method of Q-LV measurement guided optimisation for left ventricular, pacing site.

Detailed description

The study aims to demonstrate that left ventricular (LV) pacing site optimisation using high frequency (HF) ECG improves LV reverse remodeling response to Cardiac Resynchronization Therapy (CRT), compared with Q-LV (Q-wave on the surface ECG to LV Electrogram) measurement after 6 months of treatment. Participants will be implanted with a Cardiac Resynchronisation Therapy device with either pacemaker or defibrillator function. The study is a single-Centre, randomized, prospective trial. One hundred and eighty participants will be assigned to either the treatment (HF-ECG guided LV pacing site optimisation) or control (Q-LV guided LV pacing site optimisation) arm, employing a 1:1 randomization. The participants will be followed up for a period of 6 months.

Interventions

OTHERHigh Frequency ECG Mapping

A high frequency ECG map will be performed to assess the optimum left ventricular pacing site.

OTHERQ-LV Measurement

Measurement of Q wave on 12 lead ECG to LV stimulus to assess optimum left ventricular pacing site.

Sponsors

University Hospital Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

Participants will be assigned to either the treatment (HF-ECG guided LV pacing site optimisation) or control (Q-LV guided LV pacing site optimisation) arm, employing a 1:1 randomization.

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* • Eligible for implantation of a CRT-D device according to published relevant ESC and CCS guidelines; * In sinus rhythm; * NYHA class II, III or IV * Have reviewed, signed and dated an informed consent. * Age 18

Exclusion criteria

* Previous implant with a pacemaker, an ICD or a CRT device. (except upgrade from single chamber ICD with a fully functional defibrillation lead) not under recall or surveillance); * Persistent atrial arrhythmias (or cardioversion for atrial fibrillation) within the past month; * Ventricular tachyarrhythmia of transient or reversible causes such as acute myocardial infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment; * Incessant ventricular tachyarrhythmia; * Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous Coronary Intervention (PCI) within the past 4 weeks; * Correctable valvular disease that is the primary cause of heart failure; * Indication for valve repair or replacement; * Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months); * On transplant waiting list; * Previous heart transplant; * Already included in another clinical study that could confound the results of this study; * Life expectancy less than 1 year; * Inability to understand the purpose of the study; * Unavailability for scheduled follow-up or refusal to cooperate; * Age of less than 18 years; * Pregnancy; * Drug addiction or abuse; * Under guardianship.

Design outcomes

Primary

MeasureTime frameDescription
Left Ventricular Reverse Remodelling6 monthsAbsolute difference in left ventricular end systolic volume greater than or equal to 10%

Secondary

MeasureTime frameDescription
Change in NYHA Class6 monthsNYHA Class Assessment
Change in quality of life score6 monthsAssessment through Minnesota Living with Heart Failure Questionnaire
Change in left ventricular ejection fraction6 monthsImproved left ventricular ejection fraction
Reduction in QRS duration6 monthsQRS duration measured on 12 lead ECG

Countries

United Kingdom

Contacts

Primary ContactJamie Walton, Bsc
jamie.walton@uhb.nhs.uk01213712535
Backup ContactFrancisco Leyva-Leon, MD
francisco.leyva@uhb.nhs.uk01213712500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026